Jaguar Health (JAGX) Asset Writedowns and Impairment (2019)

Jaguar Health's (JAGX) quarterly Asset Writedowns and Impairment came in at $4.0 million in Q2 2019.

Jaguar Health (JAGX) Asset Writedowns and Impairment (2019) Analysis & Trends

Jaguar Health (JAGX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $4.0 million in Q2 2019.

On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $4.0 million in Q2 2019; TTM through Jun 2020 was $4.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $800000.0, changed N/A from the prior year.
Asset Writedowns and Impairment for Q2 2019 stood at $4.0 million.
Over the last five years, Asset Writedowns and Impairment for JAGX reached as high as $4.0 million in Q2 2019 and fell as low as $4.0 million in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Nanobiotix	1,774.59 Bn	1,774.53 Bn	-
2	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
3	BeOne Medicines	473.53 Bn	468.74 Bn	1.35 Bn
4	Vertex Pharmaceuticals	123.91 Bn	116.66 Bn	2.59 Bn
5	Regeneron Pharmaceuticals	71.79 Bn	63.04 Bn	3.31 Bn
6	Belite Bio	62.15 Bn	62.15 Bn	-
7	Argenx Se	54.75 Bn	49.57 Bn	1.41 Bn
8	Alnylam Pharmaceuticals	38.10 Bn	35.10 Bn	959.66 Mn
9	Revolution Medicines	36.11 Bn	36.11 Bn	-
10	Jaguar Health	509,443.80	-9.55 Mn	19.11 Mn

Download Data

Date	Value
Jun 30, 2019	4.00 Mn
Jun 30, 2019	4.00 Mn